心血管疾病住院患者的药物治疗问题
Yirga Legesse Niriayo1, Roba Kifle2, Solomon Weldegebreal Asgedom2
1Department of Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Tigray, Ethiopia. yirga.legesse@mu.edu.et.
BMC cardiovascular disorders
|January 14, 2024
概括
超过一半的住院心血管患者经历了药物治疗问题,老年和多种药物是关键的危险因素. 这凸显了针对性干预措施的必要性,以改善这种脆弱人群的药物安全性.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 临床药房 临床药房
- 心脏病学 心脏病学
背景情况:
- 最佳的心血管药物使用对于降低疾病发病率和死亡率至关重要.
- 药物治疗问题 (DTP) 可以影响药物的有效性.
- 住院的心血管病患者,特别是那些患有并发症和多药症的患者,患DTP的风险更高.
研究的目的:
- 调查住院心血管病患者中药物治疗问题 (DTP) 的患病率.
- 为了确定与该患者群体中DTP相关的促成因素.
主要方法:
- 进行了一项前性观察性研究,涉及222名住院心血管患者.
- 数据是通过患者采访和医疗记录审查收集的.
- 使用Cipolle的方法来识别DTP,通过逻辑回归分析有助于因素.
主要成果:
- 超过一半的患者 (52.7%) 经历了至少一个DTP,总共有177个DTP被确定.
- 最常见的DTP是需要额外的药物治疗 (32.4%),无效的药物治疗 (14%) 和不必要的药物治疗 (13.1%).
- 预测DTP的预测因素包括年龄 (AOR:3.97) 和多药性 (≥5种药物,AOR:2.68).
结论:
- 药物治疗问题在住院心血管患者中很普遍.
- 高龄和服用药物的数量是DTP的重要预测因素.
- 对高风险患者来说,需要增加注意力和有针对性的干预措施,以减轻DTPs.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
01:22Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
01:28Drug Therapy
45
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
45
01:26Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341